Skip to main content

Peptide Therapeutic Deal Benchmarks in Women's Health

Median Upfront
$342M
Range: $178M - $505M
Total Deal Value
$1.9B
Range: $1.2B - $2.6B
Royalty Rate
8% - 16%
Tiered up to 20%
Dev Milestones
$337M
Range: $217M - $458M
Model Your Deal

Market Analysis

Peptide Therapeutic therapies in women's health have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 peptide therapeutic asset in women's health is $342M, with total deal values reaching $1.9B. Development milestones average $337M, while regulatory milestones contribute $353M.

The women's health peptide therapeutic landscape is characterized by moderate competitive intensity with significant historical underinvestment creating unmet need. Novel hormonal approaches, non-hormonal alternatives for menopause, and precision medicine in endometriosis are driving renewed deal-making activity. The recommended deal structure allocates approximately 18% to upfront payments and 82% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for peptide therapeutic women's health deals range from 8% to 16% at the base tier, with tiered escalation reaching 12%-20% on blockbuster sales. Commercial milestones averaging $844M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a peptide therapeutic women's health licensing deal?
Based on our analysis, Phase 2 peptide therapeutic licensing deals in women's health average $342M in upfront payments, with a range of $178M to $505M depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for peptide therapeutic women's health transactions?
The median total deal value for Phase 2 peptide therapeutic assets in women's health is $1.9B, ranging from $1.2B to $2.6B. This includes development milestones ($337M), regulatory milestones ($353M), and commercial milestones ($844M).
What royalty rates are standard for peptide therapeutic deals in women's health?
Base royalty rates for peptide therapeutic women's health transactions range from 8% to 16%, with tiered escalations reaching 12%-20% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in peptide therapeutic women's health deals?
Peptide Therapeutic women's health deals allocate approximately 82% of total deal value to milestones. Development milestones ($337M) make up the largest share, followed by commercial milestones ($844M) and regulatory milestones ($353M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Women's Health

View

Monoclonal Antibody in Women's Health

View

Peptide Therapeutic in Oncology

View

Peptide Therapeutic in Neurology

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included